Harmony Biosciences to Extend Pitolisant Exclusivity to 2044 with New Orexin Agonist
ByAinvest
Tuesday, Dec 2, 2025 9:33 pm ET1min read
HRMY--
Harmony Biosciences Holdings reported positive bioequivalence results for its gastro-resistant pitolisant formulation and began a Phase 1 trial of an investigational orexin 2 receptor agonist for central disorders of hypersomnolence. This could extend pitolisant-related exclusivity towards 2044 and add a new mechanism in orexin agonism, deepening Harmony's sleep-disorder treatment portfolio. The pivotal bioequivalence success for pitolisant GR is a key near-term catalyst, but the longer-term risk of future generic competition or new therapies could pressure WAKIX-driven earnings.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet